Heterogeneity in the immunohistochemical assessment for PD-L1 and TILs (CD4 and CD8) expression both within and between tumor sites is a well-documented phenomenon that could have important implications, especially for PD-L1 accuracy as a predictive biomarker [37–39]. This evidence concerns the gene CD274 and neoplasm.